Scholarlink

<p>Bladder cancer is a fast-moving and recurrent malignancy where survival hinges on early detection and precise risk stratification. The search for robust biomarkers is urgent, and CD44v6 has emerged as a compelling candidate. In this study, we explored the clinical and functional associations of CD44v6 expression in bladder cancer. Integrated analyses of patient samples and cell lines showed that high CD44v6 expression is strongly associated with poor patient outcomes, enhanced migratory and invasive behavior, and increased resistance to cisplatin. These results suggest that CD44v6 may serve as a prognostic biomarker and a potential therapeutic target in bladder cancer. Overall, our findings highlight the translational relevance of CD44v6 and provide a foundation for future studies aimed at elucidating the mechanistic pathways underlying its role in tumor aggressiveness and chemoresistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月11日

查看全文
  • Iris Lodewijk,
  • Carolina Rubio,
  • Pontus Eriksson,
  • Ignacio A. Reina,
  • Esther Montesinos,
  • Miguel Alonso-Sánchez,
  • Laura García-Gómez,
  • Álvaro Martín de Bernardo,
  • Lucía Morales,
  • Cristian Suárez-Cabrera,
  • Mercedes Pérez-Escavy,
  • Omaira Alberquilla,
  • Rebeca Sánchez-Domínguez,
  • Félix Guerrero-Ramos,
  • Rosa García-Martin,
  • Lucía Parrilla,
  • José L. Rodríguez-Peralto,
  • Daniel Castellano,
  • Jesús M. Paramio,
  • Gottfrid Sjödahl,
  • Marta Dueñas

摘要

Bladder cancer is a fast-moving and recurrent malignancy where survival hinges on early detection and precise risk stratification. The search for robust biomarkers is urgent, and CD44v6 has emerged as a compelling candidate. In this study, we explored the clinical and functional associations of CD44v6 expression in bladder cancer. Integrated analyses of patient samples and cell lines showed that high CD44v6 expression is strongly associated with poor patient outcomes, enhanced migratory and invasive behavior, and increased resistance to cisplatin. These results suggest that CD44v6 may serve as a prognostic biomarker and a potential therapeutic target in bladder cancer. Overall, our findings highlight the translational relevance of CD44v6 and provide a foundation for future studies aimed at elucidating the mechanistic pathways underlying its role in tumor aggressiveness and chemoresistance.